Cancer cell growth is differentially affected by constitutive activation of NRF2 by KEAP1 deletion and pharmacological activation of NRF2 by the synthetic triterpenoid, RTA 405

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Probst, Brandon L ^a   McCauley, Lyndsey ^a   Trevino, Isaac ^a   Wigley, W Christian ^a   Ferguson, Deborah A ^a  

^a Reata Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYANO 3,12 DIOXOOLEANA 1,9(11) DIEN 28 OIC ACID ETHYLAMIDE; CISPLATIN; DOXORUBICIN; I KAPPA B KINASE BETA; KELCH LIKE ECH ASSOCIATED PROTEIN 1; PROTEIN BCL 2; TRANSCRIPTION FACTOR NRF2; TRITERPENOID; UNCLASSIFIED DRUG; 2-CYANO-3,12-DIOXOOLEANA-1,9(11)-DIEN-28-OIC ACID ETHYL AMIDE; I KAPPA B KINASE; IKBKB PROTEIN, HUMAN; KEAP1 PROTEIN, HUMAN; NFE2L2 PROTEIN, HUMAN; OLEANOLIC ACID; SIGNAL PEPTIDE;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; COLONY FORMATION; CONTROLLED STUDY; DRUG SENSITIVITY; FIBROBLAST; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE K RAS; PROTEIN STABILITY; TUMOR CELL LINE; ANALOGS AND DERIVATIVES; ANIMAL; APOPTOSIS; BIOSYNTHESIS; CELL TRANSFORMATION; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; MCF-7 CELL LINE; NEOPLASMS; OXIDATIVE STRESS; PATHOLOGY; SIGNAL TRANSDUCTION; SYNTHESIS;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, NEOPLASM; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; I-KAPPA B KINASE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KELCH-LIKE ECH-ASSOCIATED PROTEIN 1; MCF-7 CELLS; MICE; NEOPLASMS; NF-E2-RELATED FACTOR 2; OLEANOLIC ACID; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION;

EID: 84943173330     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0135257     Document Type: Article

References (75)

1. Liby KT, Sporn MB. Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol Rev 2012 Oct; 64(4):972-1003. doi: 10.1124/pr.111.004846 PMID: 22966038
2. Probst BL, Trevino I, McCauley L, Bumeister R, Dulubova I, Wigley WC, et al. RTA 408, A Novel Synthetic Triterpenoid with Broad Anticancer and Anti-Inflammatory Activity. PLoS ONE 2015; 10(4): e0122942. doi: 10.1371/journal.pone.0122942 PMID: 25897966
3. Hong DS, Kurzrock R, Supko JG, He X, Naing A, Wheler J, et al. A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas. Clin Cancer Res 2012 May 25.
4. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD, et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 1999 Jan 1; 13(1):76-86. PMID: 9887101
5. Cleasby A, Yon J, Day PJ, Richardson C, Tickle IJ, Williams PA, et al. Structure of the BTB Domain of Keap1 and Its Interaction with the Triterpenoid Antagonist CDDO. PLoS ONE 2014; 9(6):e98896. doi: 10.1371/journal.pone.0098896 PMID: 24896564
6. Baird L, Dinkova-Kostova AT. The cytoprotective role of the Keap1-Nrf2 pathway. Arch Toxicol 2011 Apr; 85(4):241-72. doi: 10.1007/s00204-011-0674-5 PMID: 21365312
7. Baird L, Lleres D, Swift S, Dinkova-Kostova AT. Regulatory flexibility in the Nrf2-mediated stress response is conferred by conformational cycling of the Keap1-Nrf2 protein complex. Proc Natl Acad Sci U S A 2013 Sep 17; 110(38):15259-64. doi: 10.1073/pnas.1305687110 PMID: 23986495
8. Dinkova-Kostova AT, Liby KT, Stephenson KK, Holtzclaw WD, Gao X, Suh N, et al. Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci U S A 2005 Mar 22; 102(12):4584-9. PMID: 15767573
9. Sporn MB, Liby KT, Yore MM, Fu L, Lopchuk JM, Gribble GW. New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress. J Nat Prod 2011 Mar 25; 74(3):537-45. doi: 10.1021/np100826q PMID: 21309592
10. Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, Grossman EB, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011 Jul 28; 365(4):327-36. doi: 10.1056/NEJMoa1105351 PMID: 21699484
11. Liby K, Royce DB, Williams CR, Risingsong R, Yore MM, Honda T, et al. The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice. Cancer Res 2007 Mar 15; 67(6):2414-9. PMID: 17363558
12. So JY, Wahler JE, Yoon T, Smolarek AK, Lin Y, Shih WJ, et al. Oral administration of a gemini vitamin D analog, a synthetic triterpenoid and the combination prevents mammary tumorigenesis driven by ErbB2 overexpression. Cancer Prev Res (Phila) 2013 Sep; 6(9):959-70.
13. Yates MS, Kwak MK, Egner PA, Groopman JD, Bodreddigari S, Sutter TR, et al. Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole. Cancer Res 2006 Feb 15; 66 (4):2488-94. PMID: 16489057
14. Tran K, Risingsong R, Royce D, Williams CR, Sporn MB, Liby K. The synthetic triterpenoid CDDOmethyl ester delays estrogen receptor-negative mammary carcinogenesis in polyoma middle T mice. Cancer Prev Res (Phila) 2012 May; 5(5):726-34.
15. Chauhan D, Li G, Podar K, Hideshima T, Shringarpure R, Catley L, et al. The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. Blood 2004 Apr 15; 103(8):3158-66. PMID: 15070698
16. Townson JL, Macdonald IC, Liby KT, Mackenzie L, Dales DW, Hedley BD, et al. The synthetic triterpenoid CDDO-Imidazolide suppresses experimental liver metastasis. Clin Exp Metastasis 2011 Jan 15.
17. Vannini N, Lorusso G, Cammarota R, Barberis M, Noonan DM, Sporn MB, et al. The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent. Mol Cancer Ther 2007 Dec; 6 (12):3139-46. PMID: 18065492
18. Ling X, Konopleva M, Zeng Z, Ruvolo V, Stephens LC, Schober W, et al. The novel triterpenoid C-28 methyl ester of 2-cyano-3, 12-dioxoolen-1, 9-dien-28-oic acid inhibits metastatic murine breast tumor growth through inactivation of STAT3 signaling. Cancer Res 2007 May 1; 67(9):4210-8. PMID: 17483332
19. Hiramoto K, Satoh H, Suzuki T, Moriguchi T, Pi J, Shimosegawa T, et al. Myeloid lineage-specific deletion of antioxidant system enhances tumor metastasis. Cancer Prev Res (Phila) 2014 Aug; 7(8):835-44.
20. Nagaraj S, Youn JI, Weber H, Iclozan C, Lu L, Cotter MJ, et al. Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin Cancer Res 2010 Mar 15; 16(6):1812-23. doi: 10.1158/1078-0432.CCR-09-3272 PMID: 20215551
21. Suh N, Wang Y, Honda T, Gribble GW, Dmitrovsky E, Hickey WF, et al. A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity. Cancer Res 1999 Jan 15; 59(2):336-41. PMID: 9927043
22. Konopleva M, Tsao T, Ruvolo P, Stiouf I, Estrov Z, Leysath CE, et al. Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood 2002 Jan 1; 99 (1):326-35. PMID: 11756188
23. Lapillonne H, Konopleva M, Tsao T, Gold D, McQueen T, Sutherland RL, et al. Activation of peroxisome proliferator-activated receptor gamma by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells. Cancer Res 2003 Sep 15; 63(18):5926-39. PMID: 14522919
24. Ahmad R, Raina D, Meyer C, Kufe D. Triterpenoid CDDO-methyl ester inhibits the Janus-activated kinase-1 (JAK1)->signal transducer and activator of transcription-3 (STAT3) pathway by direct inhibition of JAK1 and STAT3. Cancer Res 2008 Apr 15; 68(8):2920-6. doi: 10.1158/0008-5472.CAN-07-3036 PMID: 18413761
25. Liby K, Voong N, Williams CR, Risingsong R, Royce DB, Honda T, et al. The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells. Clin Cancer Res 2006 Jul 15; 12(14 Pt 1):4288-93. PMID: 16857804
26. Konopleva M, Zhang W, Shi YX, McQueen T, Tsao T, Abdelrahim M, et al. Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells. Mol Cancer Ther 2006 Feb; 5(2):317-28. PMID: 16505105
27. Shishodia S, Sethi G, Konopleva M, Andreeff M, Aggarwal BB. A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells. Clin Cancer Res 2006 Mar 15; 12(6):1828-38. PMID: 16551868
28. Ahmad R, Raina D, Meyer C, Kharbanda S, Kufe D. Triterpenoid CDDO-Me Blocks the NF-{kappa}B Pathway by Direct Inhibition of IKKbeta on Cys-179. J Biol Chem 2006 Nov 24; 281(47):35764-9. PMID: 16998237
29. Yore MM, Liby KT, Honda T, Gribble GW, Sporn MB. The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-{kappa}B activation through direct inhibition of I{kappa}B kinase {beta}. Mol Cancer Ther 2006 Dec; 5(12):3232-9. PMID: 17148759
30. Hayes JD, McMahon M. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci 2009 Apr; 34(4):176-88. doi: 10.1016/j.tibs.2008.12.008 PMID: 19321346
31. Sporn MB, Liby KT. NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer 2012 Aug; 12(8):564-71. doi: 10.1038/nrc3278 PMID: 22810811
32. Wang R, An J, Ji F, Jiao H, Sun H, Zhou D. Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues. Biochem Biophys Res Commun 2008 Aug 15; 373(1):151-4. doi: 10.1016/j.bbrc.2008.06.004 PMID: 18555005
33. Eades G, Yang M, Yao Y, Zhang Y, Zhou Q. miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells. J Biol Chem 2011 Sep 16.
34. Zhang P, Singh A, Yegnasubramanian S, Esopi D, Kombairaju P, Bodas M, et al. Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol Cancer Ther 2010 Feb; 9(2):336-46. doi: 10.1158/1535-7163. MCT-09-0589 PMID: 20124447
35. DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011 Jul 7; 475(7354):106-9. doi: 10.1038/nature10189 PMID: 21734707
36. Jaramillo MC, Zhang DD. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev 2013 Oct 15; 27(20):2179-91. doi: 10.1101/gad.225680.113 PMID: 24142871
37. Kensler T, Wakabayashi N. Nrf2: friend or foe for chemoprevention? Carcinogenesis 2010; 31(1):90-9. doi: 10.1093/carcin/bgp231 PMID: 19793802
38. Choi BH, Kang KS, Kwak MK. Effect of redox modulating NRF2 activators on chronic kidney disease. Molecules 2014; 19(8):12727-59. doi: 10.3390/molecules190812727 PMID: 25140450
39. Kensler TW, Egner PA, Agyeman AS, Visvanathan K, Groopman JD, Chen JG, et al. Keap1-nrf2 signaling: a target for cancer prevention by sulforaphane. Top Curr Chem 2013; 329:163-77. doi: 10.1007/128-2012-339 PMID: 22752583
40. Fox RJ, Kita M, Cohan SL, Henson LJ, Zambrano J, Scannevin RH, et al. BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety. Curr Med Res Opin 2014 Feb; 30(2):251-62. doi: 10.1185/03007995.2013.849236 PMID: 24131282
41. Stack C, Ho D, Wille E, Calingasan NY, Williams C, Liby K, et al. Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease. Free Radic Biol Med 2010 Jul 15; 49(2):147-58. doi: 10.1016/j.freeradbiomed.2010.03.017 PMID: 20338236
42. Neymotin A, Calingasan NY, Wille E, Naseri N, Petri S, Damiano M, et al. Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis. Free Radic Biol Med 2011 Jul 1; 51(1):88-96. doi: 10.1016/j.freeradbiomed.2011. 03.027 PMID: 21457778
43. Chin M, Lee CY, Chuang JC, Bumeister R, Wigley WC, Sonis ST, et al. Bardoxolone methyl analogs RTA 405 and dh404 are well tolerated and exhibit efficacy in rodent models of Type 2 diabetes and obesity. Am J Physiol Renal Physiol 2013 Jun 15; 304(12):F1438-F1446. doi: 10.1152/ajprenal.00387. 2012 PMID: 23594825
44. Ding Y, Stidham RD, Bumeister R, Trevino I, Winters A, Sprouse M, et al. The synthetic triterpenoid, RTA 405, increases the glomerular filtration rate and reduces angiotensin II-induced contraction of glomerular mesangial cells. Kidney Int 2013 May; 83(5):845-54. doi: 10.1038/ki.2012.393 PMID: 23235569
45. Alabran JL, Cheuk A, Liby K, Sporn M, Khan J, Letterio J, et al. Human Neuroblastoma Cells Rapidly Enter Cell Cycle Arrest and Apoptosis Following Exposure to C-28 derivatives of the Synthetic Triterpenoid CDDO. Cell Cycle 2008 Feb 7; 7(5).
46. Liby KT, Royce DB, Risingsong R, Williams CR, Maitra A, Hruban RH, et al. Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer. Cancer Prev Res (Phila) 2010 Nov; 3 (11):1427-34.
47. Liby K, Risingsong R, Royce DB, Williams CR, Ma T, Yore MM, et al. Triterpenoids CDDO-methyl ester or CDDO-ethyl amide and rexinoids LG100268 or NRX194204 for prevention and treatment of lung cancer in mice. Cancer Prev Res (Phila Pa) 2009 Dec; 2(12):1050-8.
48. Ohta T, Iijima K, Miyamoto M, Nakahara I, Tanaka H, Ohtsuji M, et al. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res 2008 Mar 1; 68(5):1303-9. doi: 10.1158/0008-5472.CAN-07-5003 PMID: 18316592
49. Yamamoto T, Suzuki T, Kobayashi A, Wakabayashi J, Maher J, Motohashi H, et al. Physiological significance of reactive cysteine residues of Keap1 in determining Nrf2 activity. Mol Cell Biol 2008 Apr; 28 (8):2758-70. doi: 10.1128/MCB.01704-07 PMID: 18268004
50. Tuveson DA, Shaw AT, Willis NA, Silver DP, Jackson EL, Chang S, et al. Endogenous oncogenic K-ras (G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 2004 Apr; 5(4):375-87. PMID: 15093544
51. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990 Jul 4; 82(13):1107-12. PMID: 2359136
52. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001 Dec; 25(4):402-8. PMID: 11846609
53. Shibata T, Ohta T, Tong KI, Kokubu A, Odogawa R, Tsuta K, et al. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci U S A 2008 Sep 9; 105(36):13568-73. doi: 10.1073/pnas.0806268105 PMID: 18757741
54. Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, Hoque MO, et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med 2006 Oct; 3(10):e420. PMID: 17020408
55. Carrasco RA, Stamm NB, Patel BK. One-step cellular caspase-3/7 assay. Biotechniques 2003 May; 34 (5):1064-7. PMID: 12765032
56. Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, Hoque MO, et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med 2006 Oct; 3(10):e420. PMID: 17020408
57. Hast BE, Cloer EW, Goldfarb D, Li H, Siesser PF, Yan F, et al. Cancer-Derived Mutations in KEAP1 Impair NRF2 Degradation but not Ubiquitination. Cancer Res 2014 Feb 1; 74(3):808-17. doi: 10.1158/0008-5472.CAN-13-1655 PMID: 24322982
58. Chan JY, Kwong M. Impaired expression of glutathione synthetic enzyme genes in mice with targeted deletion of the Nrf2 basic-leucine zipper protein. Biochim Biophys Acta 2000 Dec 15; 1517(1):19-26. PMID: 11118612
59. Lee DF, Kuo HP, Liu M, Chou CK, Xia W, Du Y, et al. KEAP1 E3 ligase-mediated downregulation of NF-kappaB signaling by targeting IKKbeta. Mol Cell 2009 Oct 9; 36(1):131-40. doi: 10.1016/j.molcel.2009.07.025 PMID: 19818716
60. Niture SK, Jaiswal AK. INrf2 (Keap1) targets Bcl-2 degradation and controls cellular apoptosis. Cell Death Differ 2011 Mar; 18(3):439-51. doi: 10.1038/cdd.2010.114 PMID: 20865015
61. Thu KL, Pikor LA, Chari R, Wilson IM, Macaulay CE, English JC, et al. Genetic Disruption of KEAP1/CUL3 E3 Ubiquitin Ligase Complex Components is a Key Mechanism of NF-KappaB Pathway Activation in Lung Cancer. J Thorac Oncol 2011 Sep; 6(9):1521-9. doi: 10.1097/JTO.0b013e3182289479 PMID: 21795997
62. Tian H, Zhang B, Di J, Jiang G, Chen F, Li H, et al. Keap1: one stone kills three birds Nrf2, IKKbeta and Bcl-2/Bcl-xL. Cancer Lett 2012 Dec 1; 325(1):26-34. doi: 10.1016/j.canlet.2012.06.007 PMID: 22743616
63. Singh A, Bodas M, Wakabayashi N, Bunz F, Biswal S. Gain of Nrf2 function in non-small-cell lung cancer cells confers radioresistance. Antioxid Redox Signal 2010 Dec 1; 13(11):1627-37. doi: 10.1089/ars.2010.3219 PMID: 20446773
64. Singh A, Boldin-Adamsky S, Thimmulappa RK, Rath SK, Ashush H, Coulter J, et al. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res 2008 Oct 1; 68(19):7975-84. doi: 10.1158/0008-5472.CAN-08-1401 PMID: 18829555
65. Kim KB, Lotan R, Yue P, Sporn MB, Suh N, Gribble GW, et al. Identification of a novel synthetic triterpenoid, methyl-2-cyano-3,12-dioxooleana-1,9-dien-28-oate, that potently induces caspase-mediated apoptosis in human lung cancer cells. Mol Cancer Ther 2002 Jan; 1(3):177-84. PMID: 12467212
66. Jiang ZY, Chu HX, Xi MY, Yang TT, Jia JM, Huang JJ, et al. Insight into the intermolecular recognition mechanism between Keap1 and IKKbeta combining homology modelling, protein-protein docking, molecular dynamics simulations and virtual alanine mutation. PLoS ONE 2013; 8(9):e75076. doi: 10.1371/journal.pone.0075076 PMID: 24066166
67. Wang YY, Zhe H, Zhao R. Preclinical evidences toward the use of triterpenoid CDDO-Me for solid cancer prevention and treatment. Mol Cancer 2014; 13:30. doi: 10.1186/1476-4598-13-30 PMID: 24552536
68. Yates MS, Tran QT, Dolan PM, Osburn WO, Shin S, McCulloch CC, et al. Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice. Carcinogenesis 2009 Jun; 30(6):1024-31. doi: 10.1093/carcin/bgp100 PMID: 19386581
69. Couch RD, Browning RG, Honda T, Gribble GW, Wright DL, Sporn MB, et al. Studies on the reactivity of CDDO, a promising new chemopreventive and chemotherapeutic agent: implications for a molecular mechanism of action. Bioorg Med Chem Lett 2005 May 2; 15(9):2215-9. PMID: 15837296
70. Lee OH, Jain AK, Papusha V, Jaiswal AK. An auto-regulatory loop between stress sensors INrf2 and Nrf2 controls their cellular abundance. J Biol Chem 2007 Dec 14; 282(50):36412-20. PMID: 17925401
71. Tao S, Wang S, Moghaddam SJ, Ooi A, Chapman E, Wong PK, et al. Oncogenic KRAS confers chemoresistance by upregulating NRF2. Cancer Res 2014 Oct 22.
72. Kombairaju P, Ma J, Thimmulappa RK, Yan SG, Gabrielson E, Singh A, et al. Prolonged sulforaphane treatment does not enhance tumorigenesis in oncogenic K-ras and xenograft mouse models of lung cancer. J Carcinog 2012; 11:8. doi: 10.4103/1477-3163.98459 PMID: 22919281
73. Liby KT. Synthetic triterpenoids can protect against toxicity without reducing the efficacy of treatment with Carboplatin and Paclitaxel in experimental lung cancer. Dose Response 2014 Jan; 12(1):136-51. doi: 10.2203/dose-response.13-018.Liby PMID: 24659938
74. Satoh H, Moriguchi T, Taguchi K, Takai J, Maher JM, Suzuki T, et al. Nrf2-deficiency creates a responsive microenvironment for metastasis to the lung. Carcinogenesis 2010 May 31
75. Reata Pharmaceuticals I, AbbVie. RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma)-DISCOVER. ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine ( US). 2000- [10 Jul 2015]. Available: http://ClinicalTrials.gov/show/NCT02029729NLMIdentifier: NCT02029729; 2015.